Login / Signup

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.

Giulia FerranniniLinda G MellbinFaith KiraboChinthanie RamasundarahettigeHertzel C GersteinLars Rydén
Published in: Diabetes care (2022)
Keyphrases
  • phase iii
  • study protocol
  • cardiovascular disease
  • phase ii
  • clinical trial
  • randomized controlled trial
  • open label
  • double blind